Reports for APOTEX INC
Company Name APOTEX INC |
||
---|---|---|
Totals |
||
Shortage reports |
3367 |
|
Actual shortage: | 219 (7%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 341 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-07-31 | 2019-08-02 | 90341 |
APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-06-11 | 2021-08-06 | 140772 |
APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-09-17 | 2021-10-25 | 145822 |
APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2019-12-05 | 2020-02-18 | 100265 |
APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2020-05-13 | 2020-05-19 | 114937 |
APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-05-03 | 2024-06-21 | 227082 |
APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-05-24 | 2024-06-21 | 228807 |
APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-07-18 | 2024-08-16 | 233343 |
APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-09-20 | 2024-11-08 | 238245 |
APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-12-05 | 2025-02-14 | 244915 |
APO-CEFPROZIL | 250MG | TABLET | Resolved | 2017-03-10 | 2017-10-03 | 71 |
APO-CEFPROZIL | 500MG | TABLET | Resolved | 2017-03-10 | 2017-10-03 | 74 |
APO-CEFPROZIL | 500MG | TABLET | Actual shortage | 2018-09-28 | 2018-09-28 | 62607 |
APO-CEFPROZIL | Resolved | 2018-09-28 | 2019-06-12 | 62614 | ||
APO-CEFPROZIL | Resolved | 2018-09-28 | 2019-05-24 | 62618 | ||
APO-CEFUROXIME | 500MG | TABLET | Resolved | 2017-03-17 | 2017-06-12 | 3163 |
APO-CEFUROXIME | 250MG | TABLET | Resolved | 2018-02-05 | 2018-04-14 | 38505 |
APO-CEFUROXIME | 500MG | TABLET | Resolved | 2018-02-13 | 2018-04-14 | 39650 |
APO-CEFUROXIME | 250MG | TABLET | Resolved | 2021-09-17 | 2021-10-12 | 145828 |
APO-CEFUROXIME | 250MG | TABLET | Resolved | 2023-02-02 | 2023-02-09 | 183495 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
APO-LEVOCARB - TAB 25MG/250MG | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
APO-LISINOPRIL TABLET 10 MG | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
APO-LISINOPRIL TABLET 20 MG | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
APO-LISINOPRIL TABLET 5 MG | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
APO-LOPERAMIDE - TAB 2MG | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
APO-LORAZEPAM TAB 0.5MG | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
APO-LORAZEPAM TAB 1MG | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-11-19 | 2018-11-19 | 67146 |
APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |